Servana AB (XSAT:SERV) Research & Development: kr0.00 Mil (TTM As of Mar. 2026)


What is Servana AB Research & Development?

Servana AB XSAT:SERV Research & Development is kr0.00 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Servana AB's Research & Development for the three months ended in Mar. 2026 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Servana AB  (XSAT:SERV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Servana AB Research & Development Related Terms

Servana AB Research & Development Historical Data

* Premium members only.

The historical data trend for Servana AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Servana AB Research & Development Chart

Servana AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Servana AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Servana AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Servana AB (XSAT:SERV) has a Research & Development of kr0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Servana AB and its competitors.
Is Servana AB's Research & Development too high?
Servana AB's current Research & Development is kr0.00 Mil.
How does Servana AB's Research & Development compare to ISRG and BDX?
Servana AB's Research & Development of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Servana AB and its competitors. Servana AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Servana AB stock overvalued right now?
Based on GuruFocus' analysis, Servana AB (XSAT:SERV) is currently considered Significantly Undervalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.00 — trading 68% below its estimated fair value. The current Research & Development is kr0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Servana AB (XSAT:SERV), the current Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Servana AB Business Description

Address Zinkgatan 2, Lomma, SWE, 234 35
Servana AB formerly, Medimi AB is engaged in the development, production, and marketing of medication products. It offers Medimi Pro and Medimi Smart computerized pill dispensers that are used by patients, consumers, and healthcare staff to follow their drug schedule. The company focus on the following market segments namely Pharmaceutical industry, Hospital and retirement homes, Home Health Care, Pharmacy and private care, and Connected Health (Telemedicine), E-Health and Integration in Other Systems.